CELU vs OVID โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OVID Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ovid Therapeutics Inc. Common Stock (OVID) driven by superior Valuation, Momentum & Technical, Options & Structure while CELU counters with relative strength in Growth & Margin. Fundamentally, CELU trades at N/M Forward P/E with -254.0% operating margin (-5.3% YoY revenue) versus OVID at 1.8x Forward P/E and -4693.7% operating margin (-88.3% YoY). In options structure, CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro) against OVID sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CELU Revenue | OVID Revenue | CELU Op. Margin | OVID Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2020 | $10M | $10M | -1064.0% | -645.4% | OVID |
| FY2021 | $20M | $210M | -511.2% | 59.6% | OVID |
| FY2022 | $20M | $0M | -142.4% | -3696.4% | CELU |
| FY2023 | $20M | $0M | -844.4% | -15122.7% | CELU |
| FY2024 | $50M | $0M | -70.7% | -10933.7% | CELU |
| FY2025 | $30M | $10M | -230.9% | -585.2% | CELU |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CELU | OVID | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.2M | $424.6M | Larger Scale | OVID |
| Trailing P/E Ratio Valuation | N/M | 1.8x | Lower Multiple | OVID |
| Forward P/E Ratio Valuation | N/M | 1.8x | Lower Multiple | OVID |
| Revenue Growth (YoY) Growth | -5.3% | -88.3% | Higher Growth | CELU |
| Operating Margin (TTM) Profitability | -254.0% | -4693.7% | Higher Margin | CELU |
| Net Profit Margin Profitability | -245.7% | 0.0% | Higher Margin | OVID |
| Return on Equity (ROE) Capital Efficiency | -6367.2% | -35.4% | Higher ROE | OVID |
| 52-Week Range Position Momentum | 2% ($0โ$3) | 52% ($1โ$3) | Stronger Trend | OVID |
| Beta / 30D Volatility Risk Regime | 2.01ฮฒ ยท 135% Vol | 1.04ฮฒ ยท 97% Vol | Lower Realized Risk | OVID |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 52.3 / 100 (HOLD) | Higher Composite | OVID |